There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Stryker Corporation (SYK) and Sarepta Therapeutics (SRPT) with bullish sentiments.
Stryker Corporation (SYK)
In a report released today, David Lewis from Morgan Stanley maintained a Buy rating on Stryker Corporation, with a price target of $218. The company’s shares closed on Friday at $191.58, close to its 52-week high of $191.84.
According to TipRanks.com, Lewis is a 5-star analyst with an average return of 11.6% and a 73.6% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Edwards Lifesciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Stryker Corporation with a $192.60 average price target, which is a 0.5% upside from current levels. In a report issued on March 1, Piper Jaffray also reiterated a Buy rating on the stock with a $205 price target.
See today’s analyst top recommended stocks >>
Sarepta Therapeutics (SRPT)
In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Sarepta Therapeutics, with a price target of $169. The company’s shares closed on Friday at $146.69.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 12.7% and a 66.1% success rate. Harrison covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Global Blood Therapeutics, and Alexion Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $206.56 average price target, implying a 40.8% upside from current levels. In a report issued on February 19, H.C. Wainwright also maintained a Buy rating on the stock with a $267 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
